Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRINKLE: Selumetinib granules in young children with NF1-related inoperable plexiform neurofibromas
jRCT2071220074Phase 2Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of selumetinib in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN), sponsored by Alexion Pharmaceuticals. Primary endpoints: Selumetinib AUC0-12 after single dose administration and Adverse events graded by CTCAE v5.0. Started Jan 2023; status: active, not recruiting.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on jRCT2071220074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220074.